|
|
Blood, 1 March 2004, Vol. 103, No. 5, pp. 1838-1845.
Prepublished online as a Blood First Edition Paper on October 30, 2003; DOI 10.1182/blood-2003-07-2440.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients
Ivan C. Moura,
Yves Lepelletier,
Bertrand Arnulf,
Patrick England,
Cedric Baude,
Carole Beaumont,
Ali Bazarbachi,
Marc Benhamou,
Renato C. Monteiro, and
Olivier Hermine
From the Institut National de la Santé et de la Recherche Médicale (INSERM) E-0225, Faculté deMédecine Xavier Bichat, Paris, France; Centre National de Recherche Scientifique (CNRS) FRE-2444, Hôpital Necker, Paris, France; Plateforme de Biophysique des Macromolécules et de leurs Interactions, Institut Pasteur, Paris, France; INSERM U-409, Faculté de Médecine Xavier Bichat, Paris, France; Departments of Internal Medicine and Biochemistry, American University of Beirut, Beirut, Lebanon; and Department of Clinical Hematology, Hôpital Necker, Paris, France
Adult T-cell leukemia/lymphoma (ATL) is an aggressive lymphoid proliferative disease that exists under diverse clinical forms ranging from chronic to acute. Although leukemic cells from patients with ATL exhibit an intrinsic resistance to chemotherapy, monoclonal antibodies directed against CD25 (interleukin 2 receptor  [IL-2R] antibody) have been used as specific therapeutic agents. However, significant clinical results with these antibodies have been demonstrated only in chronic forms of ATL. In contrast to resting T cells, human T-cell lymphotropic virus type 1 (HTLV-1)–infected cells constitutively express high levels of surface transferrin receptor (TfR). Herein, we report the characterization of a new monoclonal antibody (mAb A24) directed against the human TfR and the evaluation of its capacity to block the proliferation of ATL cells ex vivo. We determined that A24 binds TfR with an equilibrium constant (K'd) of 2.7 nM and competes with transferrin for binding to TfR. A24 also inhibited [55Fe]-transferrin uptake in activated T cells and blocked T-cell proliferation. Moreover, A24 reduced and impaired TfR expression and recycling, respectively. Most important, we showed that A24 blocked the ex vivo proliferation of malignant T cells from both acute and chronic forms of ATL, through induction of programmed cell death. Therefore efficient therapeutic tools to treat acute forms of ATL might be derived from A24.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Matysiak-Budnik, I. C. Moura, M. Arcos-Fajardo, C. Lebreton, S. Menard, C. Candalh, K. Ben-Khalifa, C. Dugave, H. Tamouza, G. van Niel, et al.
Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease
J. Exp. Med.,
January 21, 2008;
205(1):
143 - 154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Lepelletier, V. Camara-Clayette, H. Jin, A. Hermant, S. Coulon, M. Dussiot, M. Arcos-Fajardo, C. Baude, D. Canionni, R. Delarue, et al.
Prevention of Mantle Lymphoma Tumor Establishment by Routing Transferrin Receptor toward Lysosomal Compartments
Cancer Res.,
February 1, 2007;
67(3):
1145 - 1154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. P. Ng, G. Helguera, T. R. Daniels, S. Z. Lomas, J. A. Rodriguez, G. Schiller, B. Bonavida, S. L. Morrison, and M. L. Penichet
Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor
Blood,
October 15, 2006;
108(8):
2745 - 2754.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T. Jones, I. S. Trowbridge, and A. L. Harris
Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate.
Cancer Res.,
March 1, 2006;
66(5):
2749 - 2756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Rizvi, A. M. Evens, M. S. Tallman, B. P. Nelson, and S. T. Rosen
T-cell non-Hodgkin lymphoma
Blood,
February 15, 2006;
107(4):
1255 - 1264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. N. Stillman, D. K. Hsu, M. Pang, C. F. Brewer, P. Johnson, F.-T. Liu, and L. G. Baum
Galectin-3 and Galectin-1 Bind Distinct Cell Surface Glycoprotein Receptors to Induce T Cell Death
J. Immunol.,
January 15, 2006;
176(2):
778 - 789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. C. Moura, M. Arcos-Fajardo, A. Gdoura, V. Leroy, C. Sadaka, N. Mahlaoui, Y. Lepelletier, F. Vrtovsnik, E. Haddad, M. Benhamou, et al.
Engagement of Transferrin Receptor by Polymeric IgA1: Evidence for a Positive Feedback Loop Involving Increased Receptor Expression and Mesangial Cell Proliferation in IgA Nephropathy
J. Am. Soc. Nephrol.,
September 1, 2005;
16(9):
2667 - 2676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Regis, M. Bosticardo, L. Conti, S. De Angelis, D. Boselli, B. Tomaino, P. Bernabei, M. Giovarelli, and F. Novelli
Iron regulates T-lymphocyte sensitivity to the IFN-{gamma}/STAT1 signaling pathway in vitro and in vivo
Blood,
April 15, 2005;
105(8):
3214 - 3221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Pasquier, Y. Lepelletier, C. Baude, O. Hermine, and R. C. Monteiro
Differential expression and function of IgA receptors (CD89 and CD71) during maturation of dendritic cells
J. Leukoc. Biol.,
December 1, 2004;
76(6):
1134 - 1141.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
